{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-003130","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2022-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.456289+00:00","generated_at":"2026-06-27T00:37:52.683476+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"RxSight Q4 revenue $8.4M (+71% YoY); FY22 guidance $40-44M","bullets":["Q4 2021 revenue $8.4M, up 71% YoY; FY2021 revenue $22.6M, up 54% YoY.","Q4 net loss $(15.7)M ($(0.58)/diluted share); adjusted net loss $(12.8)M ($(0.47)/share).","Sold 45 LDDs in Q4, installed base 206; 2,959 LALs sold in Q4.","Cash and investments $159.3M; long-term debt $39.8M as of Dec 31, 2021.","FY2022 revenue expected $40-44M; gross margin 35-36%; OpEx $86-90M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-003130","json":"https://secwatch.observer/filing/0000950170-22-003130.json","markdown":"https://secwatch.observer/filing/0000950170-22-003130.md","text":"https://secwatch.observer/filing/0000950170-22-003130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017022003130/0000950170-22-003130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017022003130/rxst-20220308.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:37:52.683476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}